BIOSIMILARS 2019 - SINGAPORE’S ANNUAL MEETING ON BIOSIMILARS AND DRUG DELIVERY
View: 230
Website https://larixconferences.com/biosimilars/ |
Edit Freely
Category Biosimilars, generics, patents, pharmacology
Deadline: June 24, 2019 | Date: June 25, 2019-June 26, 2019
Venue/Country: Holiday Inn Atrium, Singapore
Updated: 2019-04-04 14:18:41 (GMT+9)
Call For Papers - CFP
biosimilars 2019Biosimilars 2019 will showcase the current year’s gathering is New Horizons in Biosimilars and Drug Delivery which will give a worldwide stage to talk of present and future of Biosimilars and drug delivery. Biosimilars are neither generic medicines nor novel treatments. Biologically-derived drugs, such as proteins, peptides and monoclonal antibodies (MAbs), are playing an increasingly important role in global healthcare. The phenomenally complex manufacturing process involved in making biosimilars is really leading contemporary science in this field and could potentially revolutionize the treatment of some conditions.DETAILS OF SINGAPORE’S ANNUAL MEETING ON BIOSIMILARS AND DRUG DELIVERY:Conference Name Place DateBiosimilars 2019 Singapore June 24-25, 2019Biosimilars versus generic drugs Biosimilars and generic drugs are versions of brand-name drugs. But biosimilars are not generics, and there are important differences between biosimilars and generic drugs. Both biosimilars and generics are approved through different abbreviated pathways. The manufacturer of a generic drug must demonstrate that the generic is bioequivalent to the brand name drug. Biosimilar manufacturers must demonstrate that the biosimilar is highly similar to the reference product. Biosimilars drugs should show there is no clinically meaningful differences between the biosimilar and the reference product in terms of safety and effectiveness.Key Discussions on Biosimilars 2019Current regulatory status of biosimilar medicines in the EUMarket access and regulatory developmentsSustainability of the biosimilar medicines sectorAdvances and convergence of regulatory scienceRegulatory requirements, scientific and operational challengesBiosimilar Development and ManufacturingPharmacovigilanceClinical TrialsLegal Considerations on BiosimilarsFDA-Approved biosimilar productsPrescribing biosimilar and generics drugs
Keywords: Accepted papers list. Acceptance Rate. EI Compendex. Engineering Index. ISTP index. ISI index. Impact Factor.
Disclaimer: ourGlocal is an open academical resource system, which anyone can edit or update. Usually, journal information updated by us, journal managers or others. So the information is old or wrong now. Specially, impact factor is changing every year. Even it was correct when updated, it may have been changed now. So please go to Thomson Reuters to confirm latest value about Journal impact factor.